The role of local ablative therapy in patients with advanced invasive mucinous adenocarcinoma of the lung
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q3Scopus Q3
- 저널
- JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY150(9) · 2024
- 피인용
- Web of Science 2Scopus 2
- FWCI (Scopus)
- 0.23
- JCR IF
- JCR 2023 2.7
- ISSN
- 0171-5216
저자
- 김수한제1저자Pusan Natl Univ, Sch Med, Dept Internal Med, 179 Gudeok Ro, Busan 49241, South Korea
- 성하영Pusan Natl Univ, Sch Med, Dept Internal Med, 179 Gudeok Ro, Busan 49241, South Korea
- 이종근Pusan Natl Univ, Pusan Natl Univ Hosp, Sch Med, Dept Thorac & Cardiovasc Surg, Pusan, South Korea
- 안효영Pusan Natl Univ, Pusan Natl Univ Hosp, Sch Med, Dept Thorac & Cardiovasc Surg, Pusan, South Korea
- 조정수Pusan Natl Univ, Pusan Natl Univ Hosp, Sch Med, Dept Thorac & Cardiovasc Surg, Pusan, South Korea
- 이호석Pusan Natl Univ, Pusan Natl Univ Hosp, Sch Med, Dept Thorac & Cardiovasc Surg, Pusan, South Korea
- 김영대Pusan Natl Univ, Pusan Natl Univ Hosp, Sch Med, Dept Thorac & Cardiovasc Surg, Pusan, South Korea
- 이민기Pusan Natl Univ, Sch Med, Dept Internal Med, 179 Gudeok Ro, Busan 49241, South Korea
- 엄중섭Pusan Natl Univ, Sch Med, Dept Internal Med, 179 Gudeok Ro, Busan 49241, South Korea
- 김미현교신저자Pusan Natl Univ, Sch Med, Dept Internal Med, 179 Gudeok Ro, Busan 49241, South Korea
초록
Purpose: Invasive mucinous adenocarcinoma (IMA) of the lungs is a rare subtype of lung adenocarcinoma with a limited understanding of its prognosis, particularly in advanced stages. This study aimed to assess the prognosis of patients with advanced IMA by focusing on treatment modalities. Methods: This single-center retrospective study evaluated 33 patients with IMAs diagnosed with advanced-stage disease or disease progression after curative treatment between 2011 and 2021. The primary outcome was overall survival (OS), and the secondary outcome was progression-free survival (PFS). OS and PFS were calculated from the date of the diagnosis of advanced IMA. Results: The study cohort included 13 patients at the initial advanced stage and 20 patients who progressed after curative treatment. Treatment modalities included conventional chemotherapy in 24 patients (72.7%), targeted therapy in seven (21.2%), immunotherapy in 13 (39.4%), and local ablative therapy (LAT) in 13 (39.4%). The median OS was 32 months (95% confidence interval [CI], 2.9–61.0), with LAT significantly associated with improved OS compared to non-LAT treatment (not reached vs. 11.3 months, p = 0.001). However, there was no significant difference in OS based on conventional chemotherapy (p = 0.396), targeted therapy (p = 0.655), or immunotherapy (p = 0.992). In multivariate analysis, LAT remained an independent prognostic factor for OS (hazard ratio, 0.125; 95% CI, 0.026–0.608; p = 0.01). PFS was 8.6 months (95% CI, 3.6–13.7), with no significant differences observed among the treatment modalities. Conclusion: Our findings suggest that LAT may provide favorable survival outcomes in patients with advanced IMA.
키워드
AdenocarcinomaLocal ablative therapyLung neoplasmsMucinousPrognosisCANCERCLASSIFICATIONFEATURESIMPACT
식별자
- Scopus EID
- 2-s2.0-85202996187
- WoS UID
- 001306375800002



로그인
연구물 목록으로